DSIP is listed for FDA advisory committee peptide discussion.
Evidence level: Primary regulatory
Sources: U.S. Food and Drug Administration
Keep copy regulatory and source-led until the review is refreshed.
Research peptide
DSIP
DSIP appears in online sleep and recovery discussions. This page tracks the topic as a source-backed index entry pending deeper evidence review.
Regulatory watch
Last reviewed 2026-07-03
Next review 2026-07-24
Evidence snapshot
Avoid sleep-treatment framing unless the exact claim is backed by reviewed primary sources.
Scheduled for FDA advisory committee discussion in July 2026.
Online discussion can blur anecdote, media commentary, and evidence.
Needs source expansion before any broader explainer is published.
Tracked claims
Early clinical studies reported that DSIP may influence sleep patterns, but results were mixed and inconclusive.
Evidence level: Peer reviewed
Sources: PubMed / NCBI
The DSIP clinical literature is dated to the 1970s-1980s and has not been advanced with modern randomized controlled trials. Treat sleep-promotion claims cautiously.
DSIP is discussed in online wellness communities as a sleep aid despite the lack of modern clinical evidence supporting its use.
Evidence level: Community discussion
Sources: PubMed / NCBI, U.S. Food and Drug Administration
Pharmacology reviews describe DSIP as a nonapeptide with reported sleep-modulating activity, but clinical significance remains unestablished. The FDA bulk risk list applies to compounded peptide products.
Free report
Get the source-quality checklist
Use the same checklist Peptide Report uses to separate DSIP claims, source records, supplier documentation, and media signals.
V1 collects email, role, and topic interest only. No medication, health-condition, dosing, or current-use data is collected in this form.
Sources on this page
Source records are stored in the repo and linked from each claim.
July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
FDA advisory committee meeting notice listing multiple peptide bulk substances scheduled for discussion.
Certain bulk drug substances for use in compounding may present significant safety risks
FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.
Effects of DSIP on sleep in humans — clinical sleep studies
Clinical studies of delta sleep-inducing peptide (DSIP) in human sleep, dating to the 1970s-1980s, with mixed and inconclusive results. The DSIP clinical literature is old and has not been advanced with modern trials.
Delta-sleep-inducing peptide: pharmacology and biological activity review
Reviews of DSIP pharmacology describe it as a nonapeptide isolated from rabbit brain extract with reported sleep-modulating activity, though clinical significance remains unestablished.
Related compounds
BPC-157
BPC-157 is widely discussed online in injury recovery and performance communities, but the public evidence and regulator...
Regulatory watchEpitalon
Epitalon is often discussed in longevity-oriented peptide content. The page starts as a regulatory watch entry and shoul...
Regulatory watchKPV
KPV is a peptide topic appearing in online wellness and research discussions. This page tracks the public source record ...
Regulatory watchSemax
Semax is often discussed online in cognitive and performance contexts. The index treats it as a source-backed watch item...
Regulatory watchStay informed